Vital Start Health Expands Virtual Mental Health Platform
Vital Start Health is co-founded by John Chuo, MD, MSBI, Chief Scientific Officer, Professor of Clinical Pediatrics at Penn Medicine, and Neonatal Quality Officer at CHOP.
Penn Medicine Facility Ushers in a New Era of Immune Health Discovery
The new facility will serve as an interdisciplinary research hub.
Carl June Speaks to the Inquirer About the Future of CAR-T Therapy
June explains the applications of CAR-T applications beyond blood cancers.
Future mRNA Vaccines May Prevent Food and Seasonal Allergies
These advancements are paving the way for potential future treatments for seasonal and food allergies in humans.
Regenxbio Showcases Promising Gene Therapy Data for Hunter Syndrome Treatment
The company reported long-term data demonstrating that its experimental treatment for Hunter syndrome, a rare genetic disorder.
MavriX Bio Receives FDA Fast Track Designation for Angelman Syndrome Treatment
MavriX is a Penn startup company based on technology developed by James Wilson, MD, PhD.
Verismo Therapeutics Announces Clinical Trial Partnership with Miltenyi Biotec
Verismo successfully manufactured its first clinical cell product using viral vector supplied by Miltenyi Bioindustry.
Dispatch Bio Named a 2025 Startup Company to Watch by Endpoints News
The company was recognized for bringing ‘universality’ to cell therapies for solid tumors.
BlueWhale Bio Reaches Major Cell Therapy Clinical Milestone
The company aims to streamline the manufacturing process for huCART19-IL18 cells in the treatment of hematologic cancers.
FDA Approval of New Treatment for Glioma Based on Penn IP
This newly approved therapy is based on technology jointly owned by Penn, Wayne State University and Penn State University.